 Connection
Rohit Katial to Anti-Asthmatic Agents
This is a "connection" page, showing publications Rohit Katial has written about Anti-Asthmatic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
4.313 |
|
|
|
-
Menzies-Gow A, Hoyte FL, Price DB, Cohen D, Barker P, Kreindler J, Jison M, Brooks CL, Papeleu P, Katial R. A Response to: Letter to the Editor Regarding "Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab". Adv Ther. 2022 08; 39(8):3862-3865.
Score: 0.596
-
Menzies-Gow A, Hoyte FL, Price DB, Cohen D, Barker P, Kreindler J, Jison M, Brooks CL, Papeleu P, Katial R. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab. Adv Ther. 2022 05; 39(5):2065-2084.
Score: 0.585
-
Katial RK, Bensch GW, Busse WW, Chipps BE, Denson JL, Gerber AN, Jacobs JS, Kraft M, Martin RJ, Nair P, Wechsler ME. Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies. J Allergy Clin Immunol Pract. 2017 Mar - Apr; 5(2S):S1-S14.
Score: 0.410
-
Katial RK. A renewed focus on safety, efficacy, and use of inhaled corticosteroids in asthma. Ann Allergy Asthma Immunol. 2016 12; 117(6):575-576.
Score: 0.406
-
Katial RK, Oppenheimer JJ, Ostrom NK, Mosnaim GS, Yancey SW, Waitkus-Edwards KR, Prillaman BA, Ortega HG. Adding montelukast to fluticasone propionate/salmeterol for control of asthma and seasonal allergic rhinitis. Allergy Asthma Proc. 2010 Jan-Feb; 31(1):68-75.
Score: 0.251
-
Gauvreau GM, Sehmi R, FitzGerald JM, Leigh R, Cockcroft DW, Davis BE, Mayers I, Boulet LP, Al-Sajee D, Salter BM, Cusack RP, Ho T, Whetstone CE, Alsaji N, Satia I, Killian KJ, Mitchell PD, Magee IP, Bergeron C, Bhutani M, Werkstr?m V, Durzynski T, Shoemaker K, Katial RK, Jison M, Newbold P, McCrae C, O'Byrne PM. Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled trial. Eur Respir J. 2024 Sep; 64(3).
Score: 0.174
-
Rivera O, Katial R, Hoyte FCL. Biologics in Asthma: Potential to Achieve Clinical Remission. Immunol Allergy Clin North Am. 2024 11; 44(4):725-736.
Score: 0.174
-
Jackson DJ, Pelaia G, Emmanuel B, Tran TN, Cohen D, Shih VH, Shavit A, Arbetter D, Katial R, Rabe APJ, Garcia Gil E, Pardal M, Nuevo J, Watt M, Boarino S, Kayaniyil S, Chaves Loureiro C, Padilla-Galo A, Nair P. Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme. Eur Respir J. 2024 Jul; 64(1).
Score: 0.172
-
Scelo G, Tran TN, Le TT, Fager?s M, Dorscheid D, Busby J, Al-Ahmad M, Al-Lehebi R, Altraja A, Beastall A, Bergeron C, Bjermer L, Bjerrum AS, Cano-Rosales DJ, Canonica GW, Carter V, Charriot J, Christoff GC, Cosio BG, Denton E, Fernandez-Sanchez MJ, Fonseca JA, Gibson PG, Goh C, Heaney LG, Heffler E, Hew M, Iwanaga T, Katial R, Koh MS, Kuna P, Larenas-Linnemann D, Lehtim?ki L, Mahboub B, Martin N, Matsumoto H, Menzies-Gow AN, Papadopoulos NG, Patel P, Perez-De-Llano L, Peters M, Pfeffer PE, Popov TA, Porsbjerg CM, Rhee CK, Sadatsafavi M, Taill? C, Torres-Duque CA, Tsai MJ, Ulrik CS, Upham JW, von B?low A, Wang E, Wechsler ME, Price DB. Exploring Definitions and Predictors of Response to Biologics for Severe Asthma. J Allergy Clin Immunol Pract. 2024 Sep; 12(9):2347-2361.
Score: 0.170
-
Li X, Newbold P, Katial R, Hirsch I, Li H, Martin UJ, Meyers DA, Bleecker ER. Multivariate Cluster Analyses to Characterize Asthma Heterogeneity and Benralizumab Responsiveness. J Allergy Clin Immunol Pract. 2024 Oct; 12(10):2732-2743.
Score: 0.169
-
Xu X, Schaefer C, Szende A, Genofre E, Katial R, Chung Y. A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective. J Manag Care Spec Pharm. 2023 Nov; 29(11):1193-1204.
Score: 0.163
-
Bleecker ER, Meyers DA, Billheimer D, Li H, Newbold P, Kwiatek J, Hirsch I, Katial R, Li X. Clinical Implications of Longitudinal Blood Eosinophil Counts in Patients With Severe Asthma. J Allergy Clin Immunol Pract. 2023 06; 11(6):1805-1813.
Score: 0.156
-
Chung Y, Katial R, Mu F, Cook EE, Young J, Yang D, Betts KA, Carstens DD. Real-world effectiveness of benralizumab: Results from the ZEPHYR 1 Study. Ann Allergy Asthma Immunol. 2022 06; 128(6):669-676.e6.
Score: 0.146
-
Menzies-Gow A, Kreindler J, Katial R, Gurnell M. Adrenal insufficiency in patients taking benralizumab as corticosteroid sparing therapy - Authors' reply. Lancet Respir Med. 2022 01; 10(1):e8.
Score: 0.143
-
Virchow JC, Katial R, Brusselle GG, Shalit Y, Garin M, McDonald M, Castro M. Safety of Reslizumab in Uncontrolled Asthma with Eosinophilia: A Pooled Analysis from 6 Trials. J Allergy Clin Immunol Pract. 2020 02; 8(2):540-548.e1.
Score: 0.122
-
Weinstein SF, Katial RK, Bardin P, Korn S, McDonald M, Garin M, Bateman ED, Hoyte FCL, Germinaro M. Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract. 2019 02; 7(2):589-596.e3.
Score: 0.115
-
Katial RK, Stelzle RC, Bonner MW, Marino M, Cantilena LR, Smith LJ. A drug interaction between zafirlukast and theophylline. Arch Intern Med. 1998 Aug 10-24; 158(15):1713-5.
Score: 0.114
-
Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, Busse WW, Wenzel S, Wu Y, Datta V, Kolbeck R, Molfino NA. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013 Nov; 132(5):1086-1096.e5.
Score: 0.080
-
Katial R, Stewart L. Exhaled nitric oxide: a test for diagnosis and control of asthma? Curr Allergy Asthma Rep. 2007 Nov; 7(6):459-63.
Score: 0.054
-
Perez-de-Llano L, Scelo G, Tran TN, Le TT, Fager?s M, Cosio BG, Peters M, Pfeffer PE, Al-Ahmad M, Al-Lehebi RO, Altraja A, Bergeron C, Bjermer LH, Bjerrum AS, Bulathsinhala L, Busby J, Cano Rosales DJ, Canonica GW, Carter VA, Charriot J, Christoff GC, Denton EJ, Dorscheid DR, Fernandez Sanchez MJ, Fonseca JA, Gibson PG, Goh CYY, Heaney LG, Heffler E, Hew M, Iwanaga T, Katial R, Koh MS, Kuna P, Larenas-Linnemann DES, Lehtim?ki L, Mahboub B, Martin N, Matsumoto H, Menzies-Gow AN, Papadopoulos NG, Popov TA, Porsbjerg CM, Patel P, Rhee CK, Sadatsafavi M, Taill? C, Torres-Duque CA, Tsai MJ, Ulrik CS, Upham JW, von B?low A, Wang E, Wechsler ME, Price DB. Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults. Am J Respir Crit Care Med. 2024 Oct 01; 210(7):869-880.
Score: 0.044
-
Porsbjerg CM, Townend J, Bergeron C, Christoff GC, Katsoulotos GP, Larenas-Linnemann D, Tran TN, Al-Lehebi R, Bosnic-Anticevich SZ, Busby J, Hew M, Kostikas K, Papadopoulos NG, Pfeffer PE, Popov TA, Rhee CK, Sadatsafavi M, Tsai MJ, Ulrik CS, Al-Ahmad M, Altraja A, Beastall A, Bulathsinhala L, Carter V, Cosio BG, Fletton K, Hansen S, Heaney LG, Hubbard RB, Kuna P, Murray RB, Nagano T, Pini L, Cano Rosales DJ, Schleich F, Wechsler ME, Amaral R, Bourdin A, Brusselle GG, Chen W, Chung LP, Denton E, Fonseca JA, Hoyte F, Jackson DJ, Katial R, Kirenga BJ, Koh MS, Lawkiedraj A, Lehtim?ki L, Liew MF, Mahboub B, Martin N, Menzies-Gow AN, Pang PH, Papaioannou AI, Patel PH, Perez-De-Llano L, Peters MJ, Ricciardi L, Rodr?guez-C?ceres B, Solarte I, Tay TR, Torres-Duque CA, Wang E, Zappa M, Abisheganaden J, Assing KD, Costello RW, Gibson PG, Heffler E, M?spero J, Nicola S, Perng Steve DW, Puggioni F, Salvi S, Sheu CC, Sirena C, Taill? C, Tan TL, Bjermer L, Canonica GW, Iwanaga T, Jim?nez-Maldonado L, Taube C, Brussino L, Price DB. Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma. Front Immunol. 2024; 15:1361891.
Score: 0.042
-
Chipps BE, Corren J, Israel E, Katial R, Lang DM, Panettieri RA, Peters SP, Farrar JR. Asthma Yardstick: Practical recommendations for a sustained step-up in asthma therapy for poorly controlled asthma. Ann Allergy Asthma Immunol. 2017 02; 118(2):133-142.e3.
Score: 0.026
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|